{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T02:53:44Z","timestamp":1764212024725,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kowa Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s13300-017-0292-1","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T01:57:01Z","timestamp":1504231021000},"page":"999-1013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study"],"prefix":"10.1007","volume":"8","author":[{"name":"On behalf of the UTOPIA study investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9020-8320","authenticated-orcid":false,"given":"Naoto","family":"Katakami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Mita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuyuki","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Umayahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Osonoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunehiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuichi","family":"Kuribayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ohtoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Sumitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Tsugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Taki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Watada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,1]]},"reference":[{"key":"292_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229\u201334.","journal-title":"N Engl J Med"},{"key":"292_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor interventional trial. Diabetes Care. 1993;16:434\u201344.","journal-title":"Diabetes Care"},{"key":"292_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.7326\/0003-4819-124-1_Part_2-199601011-00009","volume":"124","author":"M Laakso","year":"1996","unstructured":"Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The finnish studies. Ann Intern Med. 1996;124:127\u201330.","journal-title":"Ann Intern Med"},{"key":"292_CR4","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMicm066227","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"292_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129\u201339.","journal-title":"N Engl J Med"},{"key":"292_CR6","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"292_CR7","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.2337\/dc11-s220","volume":"34","author":"BM Frier","year":"2011","unstructured":"Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34[Suppl 2]:S132\u20137.","journal-title":"Diabetes Care"},{"key":"292_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2337\/dc14-0920","volume":"38","author":"K Khunti","year":"2015","unstructured":"Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38:316\u201322.","journal-title":"Diabetes Care"},{"key":"292_CR9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P Gaede","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580\u201391.","journal-title":"N Engl J Med"},{"key":"292_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clinthera.2011.04.025","volume":"33","author":"G Dailey","year":"2011","unstructured":"Dailey G. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. Clin Ther. 2011;33:665\u201378.","journal-title":"Clin Ther"},{"key":"292_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"JE Gerich","year":"2010","unstructured":"Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136\u201342.","journal-title":"Diabet Med"},{"key":"292_CR12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/db10-1328","volume":"60","author":"MJ Jurczak","year":"2011","unstructured":"Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Ponqratz RL, Zhao X. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60:890\u20138.","journal-title":"Diabetes"},{"key":"292_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499\u2013508.","journal-title":"J Clin Invest"},{"key":"292_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509\u201314.","journal-title":"J Clin Invest"},{"key":"292_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1507\/endocrj.EJ14-0335","volume":"62","author":"M Takahara","year":"2015","unstructured":"Takahara M, Shiraiwa T, Matsuoka TA, Katakami N, Shimomura I. Ameliorated pancreatic \u03b2 cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocr J. 2015;62:77\u201386.","journal-title":"Endocr J"},{"key":"292_CR16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2337\/dc12-0916","volume":"36","author":"PF Hsu","year":"2013","unstructured":"Hsu PF, Sung SH, Cheng HM, Yeh JS, Liu WL, Chan WL, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes. Diabetes Care. 2013;36:894\u2013900.","journal-title":"Diabetes Care"},{"key":"292_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262\u201374.","journal-title":"Ann Intern Med"},{"key":"292_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"292_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1124\/jpet.112.191593","volume":"341","author":"M Suzuki","year":"2012","unstructured":"Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, et al. Tofogliflozin, a potent and highly specific sodium\/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012;341:692\u2013701.","journal-title":"J Pharmacol Exp Ther"},{"key":"292_CR20","doi-asserted-by":"publisher","first-page":"E414","DOI":"10.1152\/ajpendo.00545.2012","volume":"304","author":"T Nagata","year":"2013","unstructured":"Nagata T, Fukazawa M, Honda K, Yata T, Kawai M, Yamane M, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo\u2014or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013;304:E414\u201323.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"292_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1475-2840-13-65","volume":"13","author":"K Kaku","year":"2014","unstructured":"Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, for The Tofogliflozin 003 Study Group, et al. Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.","journal-title":"Cardiovasc Diabetol"},{"key":"292_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ymgme.2004.01.018","volume":"82","author":"R Kleta","year":"2004","unstructured":"Kleta R, Stuart C, Gill FA, Gahl WA. Renal glucosuria due to SGLT2 mutations. Mol Genet Metab. 2004;82:56\u20138.","journal-title":"Mol Genet Metab"},{"key":"292_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1517\/14656566.2014.887680","volume":"15","author":"Y Tanizawa","year":"2014","unstructured":"Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K, for the Tofogliflozin 004 and 005 Study group, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15:749\u201366.","journal-title":"Expert Opin Pharmacother"},{"key":"292_CR24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.2337\/diacare.23.9.1310","volume":"23","author":"Y Yamasaki","year":"2000","unstructured":"Yamasaki Y, Kodama M, Nishizawa H, Sakamoto K, Matsuhisa M, Kajimoto Y, et al. Carotid intimamedia thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. Diabetes Care. 2000;23:1310\u20135.","journal-title":"Diabetes Care"},{"key":"292_CR25","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2337\/diacare.25.8.1308","volume":"25","author":"N Mitsuhashi","year":"2002","unstructured":"Mitsuhashi N, Onuma T, Kubo S, Takayanagi N, Honda M, Kawamori R. Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients. Diabetes Care. 2002;25:1308\u201312.","journal-title":"Diabetes Care"},{"key":"292_CR26","unstructured":"The Japan Diabetes Society. Treatment guide for diabetes 2014\u20132015, Editorial Committee members of \u201cTreatment guide for diabetes\u201d (Araki E, Inagaki N, Inoguchi T, Utsunomiya K, Tanizawa Y, Nakamura J, Noda M, Watada H, Imamura S), editors. Tokyo: Bunkodo Co., Ltd., 2014."},{"key":"292_CR27","first-page":"501","volume":"36","author":"Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine","year":"2009","unstructured":"Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine. Subcommittee for preparing guidelines for ultrasound diagnosis of carotid artery: standard method for ultrasound evaluation of carotid artery lesions. Jpn J Med Ultrasonics. 2009;36:501\u201318.","journal-title":"Jpn J Med Ultrasonics"},{"key":"292_CR28","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.amjhyper.2006.05.010","volume":"19","author":"T Yanase","year":"2006","unstructured":"Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, Okabe T, et al. Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, Intimascope. Am J Hypertens. 2006;19:1206\u201312.","journal-title":"Am J Hypertens"},{"key":"292_CR29","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1161\/01.STR.0000236632.58323.cd","volume":"37","author":"H Yokoyama","year":"2006","unstructured":"Yokoyama H, Katakami N, Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke. 2006;37:2420\u20137.","journal-title":"Stroke"},{"key":"292_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2337\/dc08-9026","volume":"32","author":"JS Skyler","year":"2009","unstructured":"Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187\u201392.","journal-title":"Diabetes Care"},{"key":"292_CR31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nrendo.2009.150","volume":"5","author":"SW Zarich","year":"2009","unstructured":"Zarich SW. Antidiabetic agents and cardiovascular risk in type 2 diabetes. Nat Rev Endocrinol. 2009;5:500\u20136.","journal-title":"Nat Rev Endocrinol"},{"key":"292_CR32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"292_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1479164114559852","volume":"12","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes Vasc Dis Res. 2015;12:90\u2013100.","journal-title":"Diabetes Vasc Dis Res"},{"key":"292_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCRESAHA.116.301135","volume":"116","author":"S Zimmer","year":"2015","unstructured":"Zimmer S, Grebe A, Latz E. Danger signaling in atherosclerosis. Circ Res. 2015;116:323\u201340.","journal-title":"Circ Res"},{"key":"292_CR35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"YH Youm","year":"2015","unstructured":"Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21:263\u20139.","journal-title":"Nat Med"},{"key":"292_CR36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","volume":"166","author":"B Neal","year":"2013","unstructured":"Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, et al. Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)\u2014a randomized placebo-controlled trial. Am Heart J. 2013;166:217\u2013223.e11.","journal-title":"Am Heart J"},{"key":"292_CR37","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","volume":"59","author":"N Sattar","year":"2016","unstructured":"Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59:1333\u20139.","journal-title":"Diabetologia"},{"key":"292_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","volume":"39","author":"M Abdul-Ghani","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717\u201325.","journal-title":"Diabetes Care"},{"key":"292_CR39","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752\u201372.","journal-title":"Circulation"},{"key":"292_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1056\/NEJM199901073400103","volume":"340","author":"DH O\u2019Leary","year":"1999","unstructured":"O\u2019Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14\u201322.","journal-title":"N Engl J Med"},{"key":"292_CR41","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","volume":"115","author":"MW Lorenz","year":"2007","unstructured":"Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459\u201367.","journal-title":"Circulation"},{"key":"292_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-128-4-199802150-00002","volume":"128","author":"HN Hodis","year":"1998","unstructured":"Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262\u20139.","journal-title":"Ann Intern Med"},{"key":"292_CR43","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00125-004-1547-8","volume":"47","author":"N Katakami","year":"2004","unstructured":"Katakami N, Yamasaki Y, Hayaishi-Okano R, Ohtoshi K, Kaneto H, Matsuhisa M, et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004;47:1906\u201313.","journal-title":"Diabetologia"},{"key":"292_CR44","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","volume":"296","author":"T Mazzone","year":"2006","unstructured":"Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D\u2019Agostino RB Sr, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572\u201381.","journal-title":"JAMA"},{"key":"292_CR45","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.5551\/jat.4663","volume":"17","author":"Y Yamasaki","year":"2010","unstructured":"Yamasaki Y, Katakami N, Furukado S, Kitagawa K, Nagatsuka K, Kashiwagi A, et al. Long term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. J Atheroscler Thromb. 2010;17:1132\u201340.","journal-title":"J Atheroscler Thromb."},{"key":"292_CR46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.diabres.2004.07.012","volume":"67","author":"Y Yamasaki","year":"2005","unstructured":"Yamasaki Y, Katakami N, Hayaishi-Okano R, Matsuhisa M, Kajimoto Y, Kosugi K, et al. Alpha-glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract. 2005;67:204\u201310.","journal-title":"Diabetes Res Clin Pract"},{"key":"292_CR47","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2337\/dc15-2145","volume":"39","author":"T Mita","year":"2016","unstructured":"Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care. 2016;39:455\u201364.","journal-title":"Diabetes Care"},{"key":"292_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2337\/dc15-0781","volume":"39","author":"T Mita","year":"2016","unstructured":"Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39:139\u201348.","journal-title":"Diabetes Care"},{"key":"292_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12933-016-0449-7","volume":"15","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, Murohara R, Taguchi T, Eguchi K, Suzuki M, Kitakaze M, on behalf of the PROTECT Study Investigators, et al. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol. 2016;15:133.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13300-017-0292-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-017-0292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-017-0292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T15:00:26Z","timestamp":1552662026000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13300-017-0292-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["292"],"URL":"https:\/\/doi.org\/10.1007\/s13300-017-0292-1","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2017,9,1]]},"assertion":[{"value":"20 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}